

Sartorius is set to grow further

28 January 2020 | News | By Ankit Kankar

Sartorius achieves significant increases in sales revenue and earnings again in 2019 and is set to grow further

2019

Key Facts

- Group sales revenue up 14.8%; order intake up 14.8%; underlying EBITDA margin 27.1%
- Continued strong growth for the Bioprocess Solutions Division, robust development of the Lab Products & Services Division
- Number of employees increased by 11% to more than 9,000
- Positive outlook for 2020: Sales growth of 10% to 13% with a further increase in earnings margin projected

Sartorius, a leading international technology partner of biopharmaceutical research and the industry, has continued on its profitable growth track in fiscal 2019. The Group grew by double digits in sales revenue, order intake and earnings, recording gains in both divisions and across all regions.

According to preliminary figures, Group sales revenue rose in constant currencies by 14.8% (reported: +16.7%) to 1,827.0 million euros. Growth was almost entirely organic as the acquisition of the cell culture media specialist Biological Industries completed in December 2019 contributed only marginally to this increase. Order intake also rose by 14.8% in constant currencies (reported: +16.7%) to 1,939.5 million euros.

"In view of revenue, earnings and jobs, Sartorius developed very dynamically again in 2019 and even better than expected at the beginning of the year. We were also successful in expanding our portfolio and in adding further key technologies through the acquisition of Biological Industries," said CEO Dr. Joachim Kreuzburg. "For Sartorius, 2020 will be a special year, not only because of our 150-year company anniversary. We aim to further grow profitably and reach the two-billion-euro mark in consolidated sales for the first time, as we had already announced in 2012 in our mid-term forecast for 2020."

Underlying EBITDA¹) rose overproportionately again relative to sales by 22.4% to 495.8 million euros; the respective margin was 27.1% (previous year: 25.9%) in line with our guidance. As expected, slightly less than one percentage point of this increase was attributable to the IFRS 16²) Standard required to be applied for the first time in 2019. Relevant net profit¹) rose by 19.2% from 175.6 million euros a year ago to 209.3 million euros, yielding earnings per ordinary share of 3.06 euros (PY: 2.56 euros) and earnings per preference share of 3.07 euros (PY: 2.57 euros).

Following the further expansion of our workforce in customer-facing functions, research and development, as well as operations, the number of Group employees rose significantly again by 11% or 900 people to 9,016.